Literature DB >> 30740430

Pharmacotherapy in conjunction with lifestyle for the treatment of obesity complications, is it enough?

Werd Al-Najim1, Carel W le Roux1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30740430      PMCID： PMC6330601          DOI： 10.21037/atm.2018.11.60

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

Review 1.  5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function.

Authors:  B L Roth; D L Willins; K Kristiansen; W K Kroeze
Journal:  Pharmacol Ther       Date:  1998-09       Impact factor: 12.310

2.  Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records.

Authors:  Alison Fildes; Judith Charlton; Caroline Rudisill; Peter Littlejohns; A Toby Prevost; Martin C Gulliford
Journal:  Am J Public Health       Date:  2015-07-16       Impact factor: 9.308

3.  Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Authors:  Benjamin M Scirica; Erin A Bohula; Jamie P Dwyer; Arman Qamar; Silvio E Inzucchi; Darren K McGuire; Anthony C Keech; Steven R Smith; Sabina A Murphy; Kyungah Im; Lawrence A Leiter; Milan Gupta; Tushar Patel; Wenfeng Miao; Carlos Perdomo; Marc P Bonaca; Christian T Ruff; Marc S Sabatine; Stephen D Wiviott
Journal:  Circulation       Date:  2019-01-15       Impact factor: 29.690

4.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.

Authors:  Michael Ej Lean; Wilma S Leslie; Alison C Barnes; Naomi Brosnahan; George Thom; Louise McCombie; Carl Peters; Sviatlana Zhyzhneuskaya; Ahmad Al-Mrabeh; Kieren G Hollingsworth; Angela M Rodrigues; Lucia Rehackova; Ashley J Adamson; Falko F Sniehotta; John C Mathers; Hazel M Ross; Yvonne McIlvenna; Renae Stefanetti; Michael Trenell; Paul Welsh; Sharon Kean; Ian Ford; Alex McConnachie; Naveed Sattar; Roy Taylor
Journal:  Lancet       Date:  2017-12-05       Impact factor: 79.321

5.  A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Authors:  Meredith C Fidler; Matilde Sanchez; Brian Raether; Neil J Weissman; Steven R Smith; William R Shanahan; Christen M Anderson
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

6.  Longitudinal study of moderate weight change and sleep-disordered breathing.

Authors:  P E Peppard; T Young; M Palta; J Dempsey; J Skatrud
Journal:  JAMA       Date:  2000-12-20       Impact factor: 56.272

7.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

8.  Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Authors:  Erin A Bohula; Benjamin M Scirica; Silvio E Inzucchi; Darren K McGuire; Anthony C Keech; Steven R Smith; Estella Kanevsky; Sabina A Murphy; Lawrence A Leiter; Jamie P Dwyer; Ramon Corbalan; Christian Hamm; Lee Kaplan; Jose Carlos Nicolau; Ton Oude Ophuis; Kausik K Ray; Mikhail Ruda; Jindrich Spinar; Tushar Patel; Wenfeng Miao; Carlos Perdomo; Bruce Francis; Shobha Dhadda; Marc P Bonaca; Christian T Ruff; Marc S Sabatine; Stephen D Wiviott
Journal:  Lancet       Date:  2018-10-04       Impact factor: 79.321

9.  Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Authors:  William J Thomsen; Andrew J Grottick; Frederique Menzaghi; Hazel Reyes-Saldana; Stephen Espitia; Diane Yuskin; Kevin Whelan; Michael Martin; Michael Morgan; Weichao Chen; Hussien Al-Shamma; Brian Smith; Derek Chalmers; Dominic Behan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.